Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression
In several series, argon plasma coagulation (APC) combined with acid suppression has led to short- or medium-term eradication of Barrett's esophagus. The present study was designed to assess the long-term outcome after this treatment. 39 patients with Barrett's esophagus, seven of them wit...
Saved in:
Published in | Endoscopy Vol. 34; no. 12; p. 950 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
01.12.2002
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | In several series, argon plasma coagulation (APC) combined with acid suppression has led to short- or medium-term eradication of Barrett's esophagus. The present study was designed to assess the long-term outcome after this treatment.
39 patients with Barrett's esophagus, seven of them with low-grade dysplasia, underwent APC and received 40 mg omeprazole daily for eradication of the metaplastic epithelium. After the treatment period, patients were randomly assigned to receive 20 or 40 mg omeprazole daily for long-term acid suppression. Histological and endoscopic changes were evaluated annually. Univariate and multivariate analyses were used to test the following 10 variables as predictors of sustained reversal of Barrett's esophagus at the end of follow-up: age, gender, length of diseased segment, presence of hiatal hernia, circumferential nature of lesion, presence of low-grade dysplasia at initial biopsy, number of coagulation sessions, result of pH monitoring under protein pump inhibitor (PPI) treatment, omeprazole dosage, and initial response to therapy (after 1 month).
The median follow-up period was 36 months (range 12 - 48). The endoscopic and histological relapse rates at 1, 12, and 24 months, and end of follow-up were, respectively, 30 % and 44 % (12/39 and 17/39), 57 % and 54 % (16/28 and 15/28), 60 % and 57 % (17/28 and 16/28), and 62 % for both rates (23/37). According to multivariate analysis, shorter length of diseased segment and normalization of pH with PPI treatment were the only independent predictors of sustained long-term re-epithelialization. Among the seven patients with low-grade dysplasia, four experienced relapse after 1 month, and during the long-term follow-up, one was lost to follow-up and all the others experienced relapse, but only one developed low-grade dysplasia again. Cancer was found in two cases after 12 and 18 months, respectively.
Persistence of acid reflux and greater length of diseased segment are the major factors associated with a high relapse rate after successful initial reversal. APC for ablation of Barrett's esophagus cannot be recommended. |
---|---|
AbstractList | In several series, argon plasma coagulation (APC) combined with acid suppression has led to short- or medium-term eradication of Barrett's esophagus. The present study was designed to assess the long-term outcome after this treatment.
39 patients with Barrett's esophagus, seven of them with low-grade dysplasia, underwent APC and received 40 mg omeprazole daily for eradication of the metaplastic epithelium. After the treatment period, patients were randomly assigned to receive 20 or 40 mg omeprazole daily for long-term acid suppression. Histological and endoscopic changes were evaluated annually. Univariate and multivariate analyses were used to test the following 10 variables as predictors of sustained reversal of Barrett's esophagus at the end of follow-up: age, gender, length of diseased segment, presence of hiatal hernia, circumferential nature of lesion, presence of low-grade dysplasia at initial biopsy, number of coagulation sessions, result of pH monitoring under protein pump inhibitor (PPI) treatment, omeprazole dosage, and initial response to therapy (after 1 month).
The median follow-up period was 36 months (range 12 - 48). The endoscopic and histological relapse rates at 1, 12, and 24 months, and end of follow-up were, respectively, 30 % and 44 % (12/39 and 17/39), 57 % and 54 % (16/28 and 15/28), 60 % and 57 % (17/28 and 16/28), and 62 % for both rates (23/37). According to multivariate analysis, shorter length of diseased segment and normalization of pH with PPI treatment were the only independent predictors of sustained long-term re-epithelialization. Among the seven patients with low-grade dysplasia, four experienced relapse after 1 month, and during the long-term follow-up, one was lost to follow-up and all the others experienced relapse, but only one developed low-grade dysplasia again. Cancer was found in two cases after 12 and 18 months, respectively.
Persistence of acid reflux and greater length of diseased segment are the major factors associated with a high relapse rate after successful initial reversal. APC for ablation of Barrett's esophagus cannot be recommended. |
Author | Kahaleh, M Nagy, N Van Laethem, J-L Devière, J Cremer, M |
Author_xml | – sequence: 1 givenname: M surname: Kahaleh fullname: Kahaleh, M organization: Department of Gastroenterology, Hôpital Erasme (Université Libre de Bruxelles), Brussels, Belgium – sequence: 2 givenname: J-L surname: Van Laethem fullname: Van Laethem, J-L – sequence: 3 givenname: N surname: Nagy fullname: Nagy, N – sequence: 4 givenname: M surname: Cremer fullname: Cremer, M – sequence: 5 givenname: J surname: Devière fullname: Devière, J |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/12471537$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kLtOwzAUhj0U0QtszOhsTAbbuTgdoeImVWIBia06sY9LUBJHtgPqG_DYBAHTf5O-4V-yWe97YuxMikspiuIqciWE4llR5XrGFkLIjGtVvs7ZMsb3nyhEcczmUuVaFplesK-t7_c8UejA-bb1n3wcAHsLDk3yIcIQyDYmNR8E3kEgM4ZAvSFoerjByad0EYGiH95wP0ZIgTCRhfoAGPa-h6HF2CEYP80tpmaqfvhoGgtxHCZ-jFN5wo4ctpFO_3TFXu5unzcPfPt0_7i53nKTyyrxWrnMSqeFtXVeF24tyQrnjFD1WpopIJHUwgmtC5crWzld5jZDvXYV2rJUK3b-yx3GuiO7G0LTYTjs_i9R35_WZqw |
CitedBy_id | crossref_primary_10_1016_j_giec_2009_07_008 crossref_primary_10_1016_S0016_5107_03_02380_0 crossref_primary_10_5009_gnl230094 crossref_primary_10_1111_j_1440_1746_2006_04369_x crossref_primary_10_1586_17434440_2_6_713 crossref_primary_10_1016_j_gie_2005_07_017 crossref_primary_10_1016_j_gie_2009_07_026 crossref_primary_10_1080_00365520510023170 crossref_primary_10_1111_j_1572_0241_2006_00709_x crossref_primary_10_1016_j_gie_2006_09_031 crossref_primary_10_1016_j_suc_2012_07_009 crossref_primary_10_1016_j_gie_2005_06_047 crossref_primary_10_1016_j_giec_2017_02_008 crossref_primary_10_3748_wjg_v23_i30_5508 crossref_primary_10_1371_journal_pone_0302204 crossref_primary_10_1097_01_mcg_0000152748_56902_02 crossref_primary_10_1097_01_pas_0000147403_33509_de crossref_primary_10_1016_S1052_5157_03_00040_0 crossref_primary_10_1111_j_1445_2197_2012_06151_x crossref_primary_10_1245_s10434_011_2163_8 crossref_primary_10_1136_pgmj_2006_054841 crossref_primary_10_1016_j_giec_2005_04_004 crossref_primary_10_1055_a_1203_5930 crossref_primary_10_1586_14737140_9_3_303 crossref_primary_10_1016_j_giec_2020_09_004 crossref_primary_10_1055_a_1230_5610 crossref_primary_10_1016_j_cdip_2005_12_002 crossref_primary_10_1111_j_1440_1746_2011_06768_x crossref_primary_10_1038_ncpgasthep0214 crossref_primary_10_1111_j_1440_1746_2007_04832_x crossref_primary_10_1016_j_bpg_2008_04_002 crossref_primary_10_1097_00001574_200307000_00011 crossref_primary_10_1016_S0016_5107_03_02002_9 crossref_primary_10_1016_j_tgie_2010_01_003 crossref_primary_10_1016_j_gie_2010_02_039 crossref_primary_10_1016_j_tgie_2005_04_001 crossref_primary_10_1111_den_13812 crossref_primary_10_1007_s10620_016_4315_y crossref_primary_10_1093_dote_doac078 crossref_primary_10_1586_egh_10_20 crossref_primary_10_22516_25007440_422 crossref_primary_10_1111_j_1572_0241_2006_00706_x crossref_primary_10_2165_00003495_200565001_00011 crossref_primary_10_1016_j_anchir_2005_11_006 crossref_primary_10_1016_j_soc_2009_03_003 crossref_primary_10_1007_s11894_017_0589_2 crossref_primary_10_1007_s10620_007_0023_y crossref_primary_10_1016_j_giec_2006_12_003 crossref_primary_10_1016_S0016_5107_04_02576_3 crossref_primary_10_1159_000080318 crossref_primary_10_1038_ajg_2012_440 crossref_primary_10_1097_SLA_0b013e318133fa85 crossref_primary_10_1159_000357185 crossref_primary_10_1007_s10620_012_2313_2 crossref_primary_10_1111_j_1572_0241_2004_30228_x crossref_primary_10_3748_wjg_v11_i8_1182 crossref_primary_10_1016_j_gie_2006_12_037 crossref_primary_10_1053_j_gastro_2009_02_062 crossref_primary_10_1111_j_1440_1746_2010_06421_x crossref_primary_10_1038_ajg_2015_322 crossref_primary_10_22516_25007440_432 crossref_primary_10_1007_s10620_018_5066_8 crossref_primary_10_1038_nrgastro_2009_90 crossref_primary_10_1111_j_1442_2050_2004_00415_x crossref_primary_10_1111_j_1365_2036_2007_03251_x crossref_primary_10_1053_j_semtcvs_2005_10_004 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1055/s-2002-35847 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
ExternalDocumentID | 12471537 |
Genre | Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .55 .GJ 0R~ 123 1UC 3O- 4.4 53G 5RE 5~~ 6PF AAIWL AAWTL ABJNI ABOCM ABZLV ACGFO ACGFS ACKTL AENEX AEVEF AHRAW AHRSK AIVKU AJGCD AKJTW ALMA_UNASSIGNED_HOLDINGS BPGNG CGR CS3 CUY CVF EBS ECM EIF EJD EXEOM F5P FD8 H13 IY8 J5H L7B N9A NPM O9- P2P Q3R QTC RIG ROL RTC UDS X7M ZGI ZXP |
ID | FETCH-LOGICAL-c418t-b2f3d1f70ddb4b5f91ed0ffc02b91c1edaee170f0775f42d8f764d3a79f8ad662 |
ISSN | 0013-726X |
IngestDate | Sat Sep 28 07:57:12 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c418t-b2f3d1f70ddb4b5f91ed0ffc02b91c1edaee170f0775f42d8f764d3a79f8ad662 |
PMID | 12471537 |
ParticipantIDs | pubmed_primary_12471537 |
PublicationCentury | 2000 |
PublicationDate | 2002-12-01 |
PublicationDateYYYYMMDD | 2002-12-01 |
PublicationDate_xml | – month: 12 year: 2002 text: 2002-12-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany |
PublicationTitle | Endoscopy |
PublicationTitleAlternate | Endoscopy |
PublicationYear | 2002 |
References | 12471547 - Endoscopy. 2002 Dec;34(12):1007-9 |
References_xml | |
SSID | ssj0013005 |
Score | 2.0648298 |
Snippet | In several series, argon plasma coagulation (APC) combined with acid suppression has led to short- or medium-term eradication of Barrett's esophagus. The... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 950 |
SubjectTerms | Adult Aged Anti-Ulcer Agents - administration & dosage Anti-Ulcer Agents - therapeutic use Barrett Esophagus - pathology Barrett Esophagus - therapy Esophagoscopy Female Follow-Up Studies Humans Hydrogen-Ion Concentration Laser Coagulation Male Middle Aged Omeprazole - administration & dosage Omeprazole - therapeutic use Recurrence Treatment Outcome |
Title | Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression |
URI | https://www.ncbi.nlm.nih.gov/pubmed/12471537 |
Volume | 34 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLamICEuiL2s8gGJw8jgOE4cH1EFqoDOqUW9VY6X6RyaRJMZIfgFnPjNPC_JpAWkwiXKxBlPJt-Xl-e3IvTKFrxWViriWF4QXkgJz5zMSFkalQtmONV-oXi0KA9P-MfT4nQ2-zmJWtpu6jf6-x_zSv4HVTgGuPos2X9AdpwUDsA-4AtbQBi218L4c9ssiZetcwdwtl_JtgvOgKGJTrf2bpgQHAQ64dqb1mNR2VXjHQ0xRlf0c-t7Gajlto9x51EpVeslMKMD7fpCzXWrlqnRVyzvqldm3m-7FEbbXDLwN6b1yS6jsf6TOofX0Pkl2-sX3y5Y-WzjmKZNRiP0QsXsmdFHdOBNmOvdtwcbBZvEeyS5m-VEsNCzcJS7yYiZ-MUmUlTGWrS_SXda-EIYPQk_kXsH7_Q0wKa7CEiDziJAkl9j9Eqt7WFoD-2JysvLhbf9DD4pSsd-GP6_pDQKuKi300vyZWjTNFeWKkFlOb6L7qS1Bn4XiXMPzWxzH906StEUD9CPkT945A8GdHHiD97xB7cO7_iDVw1O_Hnd45E9OLEH199wYA-O7MET9oT5PXvwhD0P0cmH98cHhyR15iCaZ9WG1MzlJnOCGlPzunAys4Y6pymrZabhg7I2E9T5-oqOM1M5UXKTKyFdpUxZskfoRtM2dh_hnNpCZVIzxTVXtK4M1cIxk-dSSVDvn6DH8R6edbH8ytlwd5_-deQZur1j4XN008Hzbl-A8ripXwZMfwGS5XFf |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+follow-up+and+factors+predictive+of+recurrence+in+Barrett%27s+esophagus+treated+by+argon+plasma+coagulation+and+acid+suppression&rft.jtitle=Endoscopy&rft.au=Kahaleh%2C+M&rft.au=Van+Laethem%2C+J-L&rft.au=Nagy%2C+N&rft.au=Cremer%2C+M&rft.date=2002-12-01&rft.issn=0013-726X&rft.volume=34&rft.issue=12&rft.spage=950&rft_id=info:doi/10.1055%2Fs-2002-35847&rft_id=info%3Apmid%2F12471537&rft_id=info%3Apmid%2F12471537&rft.externalDocID=12471537 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0013-726X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0013-726X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0013-726X&client=summon |